Assay of oxidized fibrinogen reactivity (OFR) as a biomarker of oxidative stress in human plasma: The role of lysine analogs

Clinical Chemistry and Laboratory Medicine

Volumn 48, Issue 3, 2010, Pages 379-382

  Selmeci, László ^a   Seres, Leila ^b   Székely, Mária ^a   Soós, Pál ^a   Acsády, György ^a  

^a SEMMELWEIS UNIVERSITY   (Hungary)

^b Gottsegen Institute of Cardiology   (Hungary)

Author keywords

Apolipoprotein(a) bound fibrinogen; Epsilonaminocaproic acid; Oxidative stress; Oxidized fibrinogen reactivity; Tranexemic acid

Indexed keywords

AMINOCAPROIC ACID; CITRIC ACID; FIBRINOGEN; LYSINE DERIVATIVE; TRANEXAMIC ACID;

ADULT; AGED; ARTICLE; BIOASSAY; BLOOD SAMPLING; CENTRIFUGATION; CONTROLLED STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; OXIDATIVE STRESS; PERIPHERAL VASCULAR DISEASE; PLASMA; PRIORITY JOURNAL;

ADULT; AGED; AGED, 80 AND OVER; AMINOCAPROIC ACIDS; APOPROTEIN(A); BIOLOGICAL MARKERS; FEMALE; FIBRINOGEN; HUMANS; KINETICS; LYSINE; MALE; MIDDLE AGED; OXIDATIVE STRESS; PERIPHERAL VASCULAR DISEASES; TRANEXAMIC ACID;

EID: 77249086275     PISSN: 14346621     EISSN: 14374331     Source Type: Journal    
DOI: 10.1515/CCLM.2010.076     Document Type: Article

References (33)

1. Collen D, Tytgat GN, Claeys H, Piessens R. Metabolism and distribution of fibrinogen. I. Fibrinogen turnover in physiological conditions in humans. Br J Hematol 1972;22:681-700.
2. Shacter E, Williams JA, Lim M, Levine RL. Differential susceptibility of plasma proteins to oxidative modification: examination by Western blot immunoassay. Free Radic Biol Med 1994;17:429-437
3. Olinescu RM, Kummerow FA. Fibrinogen is an efficient antioxidant. J Nutr Biochem 2001;12:162-169
4. Kaplan IV, Attaelmannan M, Levinson SS. Fibrinogen is an antioxidant that protects b-lipoproteins at physiological concentrations in a cell free system. Atherosclerosis 2001;158: 455-463
5. Abudu N, Miller JJ, Levinson SS. Fibrinogen is a co-antioxidant that supplements the vitamin E analog trolox in a model system. Free Radic Res 2006;40:321-331
6. Lipinski B, Federman SM, Krolewsky AS. Plasma macromolecular protein complex: interaction with fibrin and fibrinolysis. Thromb Res 1995;78:461-465
7. Kunitake ST, Carilli CT, Lau K, Protter AA, Naya-Vigne J, Kane JP. Identification of proteins associated with apolipoprotein A-I-containing lipoproteins purified by selected-affinity immunosorption. Biochemistry 1994;33:1988-1993
8. Ernst A, Helmhold M, Brunner C, Pethö-Schramm A, Armstrong VW, Müller HJ. Identification of two functionally distinct lysine-binding sites in kringle 37 and in kringles 32-36 of human apolipoprotein(a). J Biol Chem 1995;270:6227-6234
9. Park CT, Wright SD. Fibrinogen is a component of a novel lipoprotein particle: factor H-related protein (FHRP)-associated lipoprotein particle (FALP). Blood 2000;95:198-204.
10. Klose R, Fresser F, Köchl S, Parson W, Kapetanopoulos A, Fruchart-Najib J, et al. Mapping of a minimal apolipoprotein(a) interaction motif conserved in fibrin(ogen) beta- and gamma chains. J Biol Chem 2000;275:38206-38212
11. Tsurupa G, Ho-Tin-Noé B, Anglés-Cano E, Medved L. Identification and characterization of novel lysine-independent apolipoprotein( a)-binding sites in fibrin(ogen) a-C-domains. J Biol Chem 2003;278:37154-37159
12. Tsurupa G, Yakovlev S, Pechik I, Lamanuzzi LB, Anglés-Cano E, Medved L. Interaction of fibrin(ogen) with apolipoprotein( a): further characterization and identification of a novel lysine-dependent apolipoprotein(a)-binding site within the g chain 287-411 region. Biochemistry 2006;45:10624-10632
13. Witko-Sarsat V, Friedlander M, Capeillère-Blandin C, Nguyen- Khoa T, Nguyen AT, Zingraff J, et al. Advanced oxidation protein products as a novel marker of oxidative stress in uremia. Kidney Int 1996;49:1304-1313
14. Selmeci L, Seres L, Antal M, Lukács J, Regöly-Mérei A, Acsá- dy G. Advanced oxidation protein products (AOPP) for monitoring oxidative stress in critically ill patients: a simple fast and inexpensive automated technique. Clin Chem Lab Med 2005; 43:294-297
15. Selmeci L, Seres L, Soós P, Székely M, Acsády G. Kinetic assay for the determination of the oxidative stress biomarker, advanced oxidation protein products (AOPP) in the human blood plasma. Acta Physiol Hung 2008;95:209-218
16. Selmeci L, Székely M, Soós P, Seres L, Klinga N, Geiger A, et al. Human blood plasma advanced oxidation protein products (AOPP) correlates with fibrinogen levels. Free Radic Res 2006;40:952-958
17. Shacter E. Quantification and significance of protein oxidation in biological samples. Drug Metab Rev 2000;32:307-326
18. Ishida Y, Takiuchi A, Matsushima A, Inada Y. Functional consequences of tryptophan modification in human fibrinogen. Biochim Biophys Acta 1978;536:70-77
19. Henschen-Edman AH. Fibrinogen non-inherited heterogeneity and its relationship to function in health and disease. Ann NY Acad Sci 2001;936:580-593
20. Doolittle RF. The evolution of vertebrate fibrinogen. Fed Proc 1976;35:2145-2149
21. Weisel JW. Fibrinogen and fibrin. Adv Protein Chem 2005; 70:247-299
22. Kairies N, Beisel HG, Fuentes-Prior P, Tsuda R, Muta T, Iwanaga S, et al. The 2.0-A? crystal structure of tachylectin 5A provides evidence for the common origin of the innate immunity and the blood coagulation systems. Proc Natl Acad Sci USA 2001;98:13519-13524
23. Medved L, Nieuwenhuizen W. Molecular mechanisms of initiation of fibrinolysis by fibrin. Thromb Haemost 2003;89: 409-419
24. Yakovlev S, Makogonenko E, Kurochkina N, Nieuwenhuizen W, Ingham K, Medved L. Conversion of fibrinogen to fibrin: mechanism of exposure of tPA- and plasminogen-binding sites. Biochemistry 2000;39:15730-15741
25. Medved L, Tsurupa G, Yakovlev S. Conformational changes upon conversion of fibrinogen into fibrin. The mechanisms of exposure of cryptic sites. Ann NY Acad Sci 2001;936:185-204.
26. Lind L. Circulating markers of inflammation and atherosclerosis. Atherosclerosis 2003;169:203-214
27. Hansson GK. Mechanism of disease: inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 2005;352: 1685-1695
28. Hansson GK, Robertson AK, Söderberg-Nauclér C. Inflammation and atherosclerosis. Annu Rev Pathol 2006;1:297-329.
29. Torzewsky M, Lackner KJ. Initiation and progression of atherosclerosis - enzymatic or oxidative modification of low-density lipoprotein? Clin Chem Lab Med 2006;44:1389-1394
30. Packard RR, Libby P. Inflammation in atherosclerosis: from vascular biology to biomarker discovery and risk prediction. Clin Chem 2008;54:24-38.
31. Hansson GK. Atherosclerosis - an immune disease: the Anitschkov Lecture 2007. Atherosclerosis 2009;202:2-10.
32. Koenig W. Fibrin(ogen) in cardiovascular disease: an update. Thromb Haemost 2003;89:601-609
33. Stephens JW, Khanolkar MP, Bain SC. The biological relevance and measurement of plasma markers of oxidative stress in diabetes and cardiovascular disease. Atherosclerosis 2009;202: 321-329